More than 100 industry players and over 60 non-industry players currently claim to manufacture different types of cell therapies, By Roots

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry

• A detailed review of the overall landscape of companies that are engaged in the manufacturing of cell-based therapies, including information on the type of cells manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cells (autologous and allogeneic), scale of manufacturing, type of cell cultures (adherent and suspension), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, labelling, cell banking, cryopreservation, fill / finish services, and regulatory affairs management), location of headquarters and location of their respective manufacturing facilities.
• An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019 (till October), taking into consideration parameters, such as year of expansion, type of cells, scale of operation, purpose of expansion (facility expansion and new facility), location of manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
• An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019 (till November), based on various relevant parameters, such as the year of agreement, type of partnership, type of cells, and scale of operation (preclinical, clinical and commercial).
• Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of cells produced and area dedicated to manufacturing), which were further analyzed based on type of cells.
• An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), size of the organization (small, mid-sized and large firms) and key geographical regions (North America, EU and Asia Pacific).

 

To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

 

The USD 11 billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:

• Type of therapy
• T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
• Dendritic cell therapies
• Tumor cell therapies
• NK cell therapies
• Stem cell therapies

 

• Source of cells

• Autologous
• Allogeneic

 

• Scale of operation

• Clinical
• Commercial

 

• Purpose of manufacturing

• Contract manufacturing
• In-house manufacturing

 

• Key geographical regions
• North America
• Europe
• Asia Pacific
• Rest of the world

 

The Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030 report features the following companies, which we identified to be key players in this domain:

• BioNTech Innovative Manufacturing Services
• Cell Therapies
• Cell and Gene Therapy Catapult
• Center for Cell and Gene Therapy, Baylor College of Medicine
• Centre for Cell Manufacturing Ireland, National University of Ireland
• Clinical Cell and Vaccine Production Facility, University of Pennsylvania
• Cognate BioServices
• FUJIFILM
• Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
• Hitachi Chemical
• KBI Biopharma
• Laboratory for Cell and Gene Medicine, Stanford University
• Lonza
• MaSTherCell
• MEDINET
• Molecular and Cellular Therapeutics, University of Minnesota
• Newcastle Cellular Therapies Facility, Newcastle University
• Nikon CeLL innovation
• Rayne Cell Therapy Suite, King’s College London
• Roslin Cell Therapies
• Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
• Sydney Cell and Gene Therapy
• WuXi Advanced Therapies

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Overview

 

5. Regulatory Landscape
 

6. Roadmaps for Overcoming Existing Challenges

 

7. Automation Technologies for Cell Therapy Manufacturing
 

8. Profiles: Industry Players
 

9. Profiles: Non-Industry Players
 

10. Role of Non-Profit Organizations
 

11. Partnerships
 

12. Facility Expansions
 

13. Capacity Analysis

 

14. Demand Analysis

 

15. Cost Price Analysis

 

16. Make Versus Buy Decision Making Framework

 

17. Market Sizing and Opportunity Analysis

 

18. Key Insights

 

19. SWOT Analysis

 

20. Conclusion

 

21. Survey Analysis

 

22. Interview Transcripts

 

23. Appendix 1: Tabulated Data

 

24. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]